Applying stem cell technology for cardiovascular indications is not just an idea anymore.

CardioCell is currently in clinical trials using stem cells to develop highly effective, “off-the-shelf” therapeutic products for cardiovascular indication. These treatments will address the high, unmet medical needs in:

  • Acute Myocardial Infarction (AMI)
  • Chronic Heart Failure (CHF)
  • Peripheral Artery Disease (PAD)

For clinical trials, CardioCell is using cGMP allogeneic stem cells derived from the bone marrow of healthy volunteers. Manufactured in a licensed cGMP-compliant facility, the cells have been proven to be safe by Phase I clinical trials.

CardioCell’s scientific board members and clinical trial principal investigators collaborated on a peer-reviewed paper published in the Journal of Cardiovascular Medicine. For more detail, CLICK HERE.
Clinical Trials Update
Northwestern University’s Phase IIa clinical trial for chronic heart failure of non-ischemic cardiomyopathy is currently enrolling new patients in the Chicago area. All participants will receive CardioCell's stem cell treatment. For more information, CLICK HERE.
Latest News
CardioCell launches trial to assess stem cell therapy for chronic HF. The initiation of a phase 2a trial of ischemia-tolerant stem cell therapy for patients with chronic HF due to nonischemic cardiomyopathy has been announced. READ FULL ARTICLE.